Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

By sjmartinez • January 26, 2023

Gao Y, Stein MM, Kase M, Cummings AL, Bharanikumar R, Lau D, Garon EB, Patel SP. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. Cancer Immunol Immunother. 2023 Feb;72(2):339-350. doi: 10.1007/s00262-022-03252-y. Epub 2022 Jul 26. PMID: 35881197; PMCID: PMC9870967.

Tags: Checkpoint blockade, Hematology/Oncology, immunotherapy, Non-small cell lung cancer, PD-L1, Publications, Transcriptomics, Tumor immune microenvironment

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di[...]

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]

Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID:[...]